KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Amortization - Intangibles (2022 - 2025)

Halozyme Therapeutics (HALO) has disclosed Amortization - Intangibles for 4 consecutive years, with $23.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Amortization - Intangibles rose 31.61% to $23.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $76.7 million, a 7.9% increase, with the full-year FY2025 number at $76.7 million, up 7.9% from a year prior.
  • Amortization - Intangibles was $23.4 million for Q4 2025 at Halozyme Therapeutics, up from $17.8 million in the prior quarter.
  • In the past five years, Amortization - Intangibles ranged from a high of $27.2 million in Q3 2022 to a low of $4.6 million in Q4 2022.
  • A 4-year average of $17.6 million and a median of $17.8 million in 2023 define the central range for Amortization - Intangibles.
  • Biggest YoY gain for Amortization - Intangibles was 290.2% in 2023; the steepest drop was 25.2% in 2023.
  • Halozyme Therapeutics' Amortization - Intangibles stood at $4.6 million in 2022, then soared by 290.2% to $17.8 million in 2023, then changed by 0.0% to $17.8 million in 2024, then skyrocketed by 31.61% to $23.4 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Amortization - Intangibles are $23.4 million (Q4 2025), $17.8 million (Q3 2025), and $17.8 million (Q2 2025).